A Dwindling Matter: An Analysis of Medicare Reimbursement for Endocrine Surgery Procedures From 2000 to 2023.

Objective: To evaluate Medicare reimbursement trends for endocrine surgeries from 2000 to 2023.

Background: As the population ages, demand for endocrine surgeries is expected to increase. Understanding reimbursement trends is essential to ensure the financial sustainability of endocrine surgery.

Methods: Data were extracted from Medicare Inpatient and Outpatient Hospital data sets, National Summary, and Physician Fee Look-up Files for nine common thyroid, parathyroid, and adrenal surgeries. Data were adjusted for inflation. Descriptive statistics, compound annual growth rate (CAGR), and linear regression models were built to evaluate practice and reimbursement trends.

Results: From 2000 to 2023, there was a 63.8% increase in endocrine surgery volume. However, inflation-adjusted average procedure reimbursements decreased by 43.2% from $1709 to $972 (CAGR-2.4%), which is the largest decrease for any surgical subspecialty reported in the published literature. At the current CAGR, the average estimated reimbursement is projected to decrease to $868 by 2030 ( P <0.001). Average facility reimbursements for inpatient and outpatient hospitalizations increased. However, substantial practice pattern shifts in the study period led to decreased overall facility reimbursements, with a $17.9 million decrease in total inpatient reimbursements between 2016 and 2021 that was only partially offset by a $3.2 million increase in outpatient hospital reimbursements.

Conclusion: Medicare procedure reimbursements for endocrine surgeries have been outpaced by inflation, with large decreases since 2000. Concurrent changes in practice patterns have also resulted in markedly fewer inpatient stays, leading to lower total facility reimbursements. Our data raise concern over the financial sustainability of the endocrine surgery field as the demand for endocrine surgery procedures increases.